Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

New Jersey Surges to the Top in Biotech Growth Potential Category

New Jersey signPrinceton, NJ, October 26, 2015 ― New Jersey’s dominance in biotechnology was validated with a top ranking nationally in the Biotech Growth Potential category in Business Facilities Magazine’s Annual Rankings Report released on July 31.

New Jersey surged to the top of the annual biotech growth assessment as a result of its ability to attract new players and grant funding, leverage its world-class research hubs, and its ability to support startups and develop new industry clusters.

Home to 14 of the world’s largest biopharmaceutical companies and largest clinical research organizations, New Jersey also was ranked #2 in Biotech Strength (Drugs/Pharma) in the Annual Rankings.

The state’s position as a hub of biotech and pharmaceutical business also was confirmed in a survey of BioSpace readers also released this week.  An overwhelming majority of respondents, 63.42 percent, believe New Jersey will continue to attract biotech and life science companies.

So far this year, 16 of the 27 new products approved by the FDA came from companies with a significant footprint in New Jersey.  BioSpace is a leading online community for life sciences professionals.

“New Jersey has the perfect ecosystem to support biotech growth—a thriving biopharmaceutical sector, world-class universities and research facilities, and a highly-educated workforce that makes it possible to recruit top talent,” said Michele Brown, President and CEO of Choose New Jersey.

“We’re proud of the collaborative environment that has supported the life sciences industry for decades, and gratified that the industry acknowledges New Jersey’s assets and strengths,” Brown added.

Dean J. Paranicas, President and Chief Executive Officer, HealthCare Institute of New Jersey (HINJ), said, “This recognition of New Jersey reinforces its reputation as the ‘Medicine Chest of the World.’  The effort to energize our innovation ecosystem, which will attract new industry investment in the state and help resident companies grow, holds great promise to increase the life sciences’ significant impact on New Jersey’s economy and the state’s already tremendous impact on global health.”

“It’s exciting to see New Jersey’s robust ecosystem recognized as a leading biotech hub,” said Debbie Hart, President and CEO of BioNJ.  “With our amazing pool of talent, prominent research universities and legacy of big pharma, New Jersey’s innovative life sciences community continues to develop and bring to market the treatments and cures that Patients need.

Choose New Jersey‘s mission is to encourage and nurture economic growth throughout New Jersey, including making the state’s most distressed cities engines for growth and opportunity. New Jersey is one of only a handful of states that has charged a non-governmental agency with state-wide marketing efforts for economic development purposes.

Founded in 2010, Choose New Jersey, Inc. is part of the Partnership for Action (PFA), a four-pronged public-private approach to economic development that serves as the starting point for all initiatives, policies and efforts related to growing New Jersey’s economy and creating sustainable jobs.  The PFA includes:

  • Choose New Jersey

Led by Lt. Governor Kim Guadagno, the PFA aims to assist businesses of all sizes and industries through relationship building, promoting New Jersey’s diverse portfolio of financial incentives and resources, maximizing the effectiveness of these pro-growth policies and assisting businesses in navigating state government and programs.